keyword
https://read.qxmd.com/read/38630549/navigating-resistance-to-alk-inhibitors-in-the-lorlatinib-era-a-comprehensive-perspective-on-nsclc
#1
REVIEW
Maria Gemelli, Adriana Albini, Gianpiero Catalano, Matteo Incarbone, Maria Cannone, Emanuela Balladore, Riccardo Ricotta, Giuseppe Pelosi
INTRODUCTION: The emergence of anaplastic lymphoma kinase (ALK) rearrangements in non-small cell lung cancer (NSCLC) has revolutionized targeted therapy. This dynamic landscape, featuring novel ALK inhibitors and combination therapies, necessitates a profound understanding of resistance mechanisms for effective treatment strategies. Recognizing two primary categories - on-target and off-target resistance - underscores the need for comprehensive assessment. AREAS COVERED: This review delves into the intricacies of resistance to ALK inhibitors, exploring complexities in identification and management...
April 17, 2024: Expert Review of Anticancer Therapy
https://read.qxmd.com/read/38630129/monocyte-to-platelets-ratio-mpr-at-diagnosis-is-associated-with-inferior-progression-free-survival-in-patients-with-mantle-cell-lymphoma-a-multi-center-real-life-survey
#2
JOURNAL ARTICLE
Andrea Duminuco, Alessandra Romano, Isacco Ferrarini, Gabriella Santuccio, Annalisa Chiarenza, Amalia Figuera, Laura Anastasia Caruso, Giovanna Motta, Giuseppe Alberto Palumbo, Carlo Mogno, Alessia Moioli, Francesco Di Raimondo, Carlo Visco
Mantle cell lymphoma (MCL) pathogenesis is strongly related to the role of the tumor immune microenvironment (TIME) in which MCL cells proliferate. TIME cells can produce growth signals influencing MCL cells' survival and exert an antitumoral immune response suppression. The activity of TIME cells might be mirrored by some ratios of peripheral blood cell subpopulations, such as the monocyte-to-platelet ratio (MPR). We reviewed the clinical features of 165 consecutive MCL patients newly diagnosed and not eligible for autologous stem cell transplantation (both for age or comorbidities) who accessed two Italian Centers between 2006 and 2020...
April 17, 2024: Annals of Hematology
https://read.qxmd.com/read/38629506/zinc-ameliorates-acrylamide-induced-oxidative-stress-and-apoptosis-in-testicular-cells-via-nrf2-ho-1-nfkb-and-bax-bcl2-signaling-pathway
#3
JOURNAL ARTICLE
Ayodeji Johnson Ajibare, Adeyemi Fatai Odetayo, Olabode Oluwadare Akintoye, Luqman Aribidesi Olayaki
BACKGROUND: Acrylamide is a toxic substance formed in some foods that require high-temperature cooking processes and has been implicated as a gonadotoxic agent. Zinc, on the other hand, is a known antioxidant with fertility-enhancing properties. Hence, this study was designed to explore the possible ameliorative effect of zinc in acrylamide-induced gonadotoxicity. METHODS: Twenty-four male Wistar rats were randomized into control, acrylamide (10 mg/kg of acrylamide), acrylamide + 1 mg/kg of zinc, and acrylamide + 3 mg/kg of zinc...
December 2024: Redox Report: Communications in Free Radical Research
https://read.qxmd.com/read/38628779/the-antiapoptotic-effects-of-conditioned-medium-from-bone-marrow-derived-mesenchymal-stromal-stem-cells-on-cyclophosphamide-induced-testicular-damage-in-rat-an-experimental-study
#4
JOURNAL ARTICLE
Zeynab Esmailpour, Soheila Madadi, Maryam Baazm
BACKGROUND: Cyclophosphamide (CP) has some negative effects on the reproductive system. Stem cells and their metabolites are being utilized to enhance fertility after chemotherapy. OBJECTIVE: This study aimed to investigate the impact of conditioned medium (CM) derived from bone marrow mesenchymal stromal stem cells (BM-MSCs) on the toxic effects of CP on testicles. MATERIALS AND METHODS: BM-MSCs were isolated, a CM was collected and 25-fold concentrated...
February 2024: International Journal of Reproductive Biomedicine (Yazd, Iran)
https://read.qxmd.com/read/38628632/application-of-machine-learning-in-the-management-of-lymphoma-current-practice-and-future-prospects
#5
REVIEW
Junyun Yuan, Ya Zhang, Xin Wang
In the past decade, digitization of medical records and multiomics data analysis in lymphoma has led to the accessibility of high-dimensional records. The digitization of medical records, the visualization of extensive volume data extracted from medical images, and the integration of multiomics methods into clinical decision-making have produced many datasets. As a promising auxiliary tool, machine learning (ML) intends to extract homologous features in large-scale data sets and encode them into various patterns to complete complicated tasks...
2024: Digital Health
https://read.qxmd.com/read/38627969/evolution-of-the-clinical-stage-hyperactive-tcbuster-transposase-as-a-platform-for-robust-non-viral-production-of-adoptive-cellular-therapies
#6
JOURNAL ARTICLE
Joseph G Skeate, Emily J Pomeroy, Nicholas J Slipek, Bryan J Jones, Bryce J Wick, Jae-Woong Chang, Walker S Lahr, Erin M Stelljes, Xiaobai Patrinostro, Blake Barnes, Trevor Zarecki, Joshua B Krueger, Jacob E Bridge, Gabrielle M Robbins, Madeline D McCormick, John R Leerar, Kari T Wenzel, Kathlyn M Hornberger, Kirsti Walker, Dalton Smedley, David A Largaespada, Neil Otto, Beau R Webber, Branden S Moriarity
Cellular therapies for the treatment of human diseases, such as chimeric antigen receptor (CAR) T and NK cells have shown remarkable clinical efficacy in treating hematological malignancies, however current methods mainly utilize viral vectors which are limited by their cargo size capacities, high cost, and long timelines for production of clinical reagent. Delivery of genetic cargo via DNA transposon engineering is a more timely and cost-effective approach, yet has been held back by less efficient integration rates...
April 15, 2024: Molecular Therapy
https://read.qxmd.com/read/38627904/evaluate-the-in-vitro-effect-of-anthracycline-and-alkylating-cytophosphane-chemotherapeutics-on-dopaminergic-neurons
#7
JOURNAL ARTICLE
Darshini Desai, Mohammed Majrashi, Suhrud Pathak, Mohammed Almaghrabi, Keyi Liu, Satyanarayana R Pondugula, Amit K Tiwari, R Jayachandra Babu, Jack Deruiter, Muralikrishnan Dhanasekaran
BACKGROUND: Iatrogenesis is an inevitable global threat to healthcare that drastically increases morbidity and mortality. Cancer is a fatal pathological condition that affects people of different ages, sexes, and races around the world. In addition to the detrimental cancer pathology, one of the most common contraindications and challenges observed in cancer patients is severe adverse drug effects and hypersensitivity reactions induced by chemotherapy. Chemotherapy-induced cognitive neurotoxicity is clinically referred to as Chemotherapy-induced cognitive impairment (CICI), chemobrain, or chemofog...
April 2024: Cancer reports
https://read.qxmd.com/read/38627366/phase-ii-study-of-novel-orally-pi3k%C3%AE-%C3%AE-inhibitor-tq-b3525-in-relapsed-and-or-refractory-follicular-lymphoma
#8
JOURNAL ARTICLE
Huaqing Wang, Jifeng Feng, Yanyan Liu, Zhengzi Qian, Da Gao, Xuehong Ran, Hui Zhou, Lihong Liu, Binghua Wang, Meiyun Fang, Hebing Zhou, Zhenqian Huang, Shi Tao, Zhuowen Chen, Liping Su, Hang Su, Yu Yang, Xiaobao Xie, Huijing Wu, Ping Sun, Guoyu Hu, Aibin Liang, Zhiming Li
This registration study assessed clinical outcomes of TQ-B3525, the dual phosphatidylinositol-3-kinase (PI3K) α/δ inhibitor, in relapsed and/or refractory follicular lymphoma (R/R FL). This phase II study (ClinicalTrials.gov NCT04324879. Registered March 27, 2020) comprised run-in stage and stage 2. R/R FL patients after ≥2 lines therapies received oral 20 mg TQ-B3525 once daily in a 28-day cycle until intolerable toxicity or disease progression. Primary endpoint was independent review committee (IRC)-assessed objective response rate (ORR)...
April 17, 2024: Signal Transduction and Targeted Therapy
https://read.qxmd.com/read/38627181/practical-aspects-of-immunotherapy-a-report-from-the-20th-international-myeloma-society-ims-annual-meeting
#9
JOURNAL ARTICLE
Noopur S Raje, Adam D Cohen, Krina K Patel, Niels W C J van de Donk, Joshua Richter, Jesus San-Miguel
Immunotherapeutic strategies, specifically T-cell-redirected therapies, have been transformative in the context of multiple myeloma (MM). With the approval of two chimeric antigen receptor T-cell (CAR-T) drug products and three bispecific antibodies/T-cell engagers (bsAbs/TCEs) in relapsed/refractory MM (RRMM), the 20th annual IMS meeting dedicated a session to the practical aspects of these therapies. Here, we highlight the discussion during this session, including the role of CAR-T and bsAb therapies in frontline MM treatment, management of acute toxicities, prevention and management of infections, and finally treatment sequencing of T-cell redirected therapies...
March 22, 2024: Clinical Lymphoma, Myeloma & Leukemia
https://read.qxmd.com/read/38626846/enhancing-breast-cancer-treatment-comprehensive-study-of-gefitinib-loaded-poloxamer-407-tpgs-mixed-micelles-through-design-development-in-silico-modelling-in-vitro-testing-and-ex-vivo-characterization
#10
JOURNAL ARTICLE
Padakanti Sandeep Chary, Ankush Bansode, Naveen Rajana, Valmala Bhavana, Siva Singothu, Anamika Sharma, Santosh Kumar Guru, Vasundhra Bhandari, Neelesh Kumar Mehra
Breast cancer continues to pose a substantial global health challenge, emphasizing the critical need for the advancement of novel therapeutic approaches. Key players in the regulation of apoptosis, a fundamental process in cell death, are the B-cell lymphoma 2 (Bcl-2) family proteins, namely Bcl-2 and Bax. These proteins have garnered attention as highly promising targets for the treatment of breast cancer. Targeting the overexpressed anti-apoptotic Bcl-2 protein in breast cancer, Gefitinib (GEF), an EGFR (Epidermal Growth Factor Receptor) inhibitor, emerges as a potential solution...
April 14, 2024: International Journal of Pharmaceutics
https://read.qxmd.com/read/38626800/chronic-lymphocytic-leukemia-small-lymphocytic-lymphoma-version-2-2024
#11
JOURNAL ARTICLE
William G Wierda, Jennifer Brown, Jeremy S Abramson, Farrukh Awan, Syed F Bilgrami, Greg Bociek, Danielle Brander, Matthew Cortese, Larry Cripe, Randall S Davis, Herbert Eradat, Bita Fakhri, Christopher D Fletcher, Sameh Gaballa, Muhammad Saad Hamid, Brian Hill, Paul Kaesberg, Brad Kahl, Manali Kamdar, Thomas J Kipps, Shuo Ma, Claudio Mosse, Shazia Nakhoda, Sameer Parikh, Andrew Schorr, Stephen Schuster, Madhav Seshadri, Tanya Siddiqi, Deborah M Stephens, Meghan Thompson, Chaitra Ujjani, Riccardo Valdez, Nina Wagner-Johnston, Jennifer A Woyach, Hema Sundar, Mary Dwyer
Chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL) are essentially different manifestations of the same disease that are similarly managed. A number of molecular and cytogenetic variables with prognostic implications have been identified. Undetectable minimal residual disease at the end of treatment with chemoimmunotherapy or venetoclax-based combination regimens is an independent predictor of improved survival among patients with previously untreated or relapsed/refractory CLL/SLL. The selection of treatment is based on the disease stage, presence or absence of del(17p) or TP53 mutation, immunoglobulin heavy chain variable region mutation status, patient age, performance status, comorbid conditions, and the agent's toxicity profile...
April 2024: Journal of the National Comprehensive Cancer Network: JNCCN
https://read.qxmd.com/read/38626509/a-multi-instance-tumor-subtype-classification-method-for-small-pet-datasets-using-ra-dl-attention-module-guided-deep-feature-extraction-with-radiomics-features
#12
JOURNAL ARTICLE
Zhaoshuo Diao, Huiyan Jiang
BACKGROUND: Positron emission tomography (PET) is extensively employed for diagnosing and staging various tumors, including liver cancer, lung cancer, and lymphoma. Accurate subtype classification of tumors plays a crucial role in formulating effective treatment plans for patients. Notably, lymphoma comprises subtypes like diffuse large B-cell lymphoma and Hodgkin's lymphoma, while lung cancer encompasses adenocarcinoma, small cell carcinoma, and squamous cell carcinoma. Similarly, liver cancer consists of subtypes such as cholangiocarcinoma and hepatocellular carcinoma...
April 9, 2024: Computers in Biology and Medicine
https://read.qxmd.com/read/38626366/real-world-health-care-resource-use-and-costs-among-patients-with-chronic-lymphocytic-leukemia-treated-with-venetoclax-based-and-bruton-tyrosine-kinase-inhibitor-based-regimens-in-the-second-line-setting
#13
JOURNAL ARTICLE
Bita Fakhri, Nnadozie Emechebe, Beenish S Manzoor, Dureshahwar Jawaid, Hasan Alhasani, Melanie Edwards, Hande H Tuncer
PURPOSE: Real-world evidence comparing health care resource use (HRU) and costs between novel targeted therapies among patients with chronic lymphocytic leukemia (CLL) is lacking. We compared all-cause and CLL-specific HRU and costs between patients initiated on B-cell lymphoma 2 inhibitor (venetoclax)- or Bruton tyrosine kinase inhibitor (BTKi)-based regimens in the second-line (2L) setting. METHODS: This is a retrospective observational study using Optum Clinformatics Data Mart of adult patients with CLL/small lymphocytic lymphoma who received 2L venetoclax- or BTKi-based regimens (January 2018-December 2021) for the first time and had ≥one CLL diagnostic claim after 2L initiation and ≥two claims for venetoclax or BTKi...
April 16, 2024: JCO oncology practice
https://read.qxmd.com/read/38626292/bcl2a1-neoepitopes-elicited-cytotoxic-t-lymphocytes-are-a-promising-individualized-immunotherapy-of-pancreatic-cancer
#14
JOURNAL ARTICLE
Shengzhe Lin, Jingwen Hong, Suxin Wu, Chenlu Zhu, Fang Liu, Wansong Lin, Xinran Cai, Yunbin Ye, Yanling Chen
Conventional treatments have shown a limited efficacy for pancreatic cancer, and immunotherapy is an emerging option for treatment of this highly fatal malignancy. Neoantigen is critical to improving the efficacy of tumor-specific immunotherapy. The cancer and peripheral blood specimens from human leukocyte antigen (HLA)-A0201 positive pancreatic cancer patient were subjected to next-generation sequencing and bioinformatics analyses were performed to screen high-affinity and highly stable neoepitopes. The activation of cytotoxic T lymphocytes (CTLs) by the mutBCL2A111-20 neoepitope targeting B-cell lymphoma 2-related protein A1 (BCL2A1) mutant epitope was investigated, and the cytotoxicity of mutBCL2A111-20 neoepitope-specific CTLs to pancreatic cancer cells was evaluated...
April 16, 2024: Journal of Leukocyte Biology
https://read.qxmd.com/read/38626148/real-world-status-of-treatment-for-lymphoid-neoplasms-developed-during-the-course-of-myeloproliferative-neoplasms-in-japan
#15
MULTICENTER STUDY
Yoko Edahiro, Tomonori Ochiai, Yoshinori Hashimoto, Michiko Ichii, Takeshi Okatani, Hiromi Omura, Kei Nakajima, Makoto Sasaki, Jun Ando, Tomoiku Takaku, Michiaki Koike, Koh Izumiyama, Junji Hiraga, Tomofumi Yano, Kensuke Usuki, Eiichi Ohtsuka, Kenji Yokoyama, Tatsuo Oyake, Naoki Takahashi, Tetsuya Nishida, Takafumi Nakao, Yasutaka Fukuda, Takashi Akasaka, Atsuko Mugitani, Miki Ando, Norio Komatsu
OBJECTIVES: Patients with myeloproliferative neoplasms (MPNs) are at higher risk of developing secondary malignancies. In this study, we focused on patients with MPNs that complicated lymphoid neoplasms. To analyze the real-world status of lymphoid neoplasm treatment in patients with pre-existing MPNs in Japan, we conducted a multicenter retrospective study. METHODS: Questionnaires were sent to collect the data on patients who were first diagnosed with either polycythemia vera, essential thrombocythemia or myelofibrosis and who later were complicated with lymphoid neoplasms defined as malignant lymphoma, multiple myeloma, or chronic lymphocytic leukemia/small cell lymphoma...
December 2024: Hematology (Amsterdam, Netherlands)
https://read.qxmd.com/read/38625832/histopathological-staging-and-differential-diagnosis-of-marginal-zone-lymphoma-of-gastric-mucosa-associated-lymphoid-tissue
#16
JOURNAL ARTICLE
Dong-Feng Ge, Yang-Kun Wang, Shen-Lin Li, Xiong-Fei Zou, Ling-Chao Kong, Wei-Yi Deng, Su-Nan Wang
The purpose of this study was to explore the histopathological staging and differential diagnosis of marginal zone lymphoma in gastric mucosa-associated lymphoid tissue (MALT lymphoma). We performed detailed histomorphology and immunohistochemistry investigations as well as genetic testing on endoscopic biopsy and endoscopic mucosal resection specimens from 18 patients with gastric MALT lymphoma. We found that gastric MALT lymphoma typically begins as a small, isolated area outside the lymphoid follicular mantle zone or proliferates in a multifocal, patchy manner, gradually spreads to the interfollicular zone, forming diffuse proliferation, invades the gastric mucosal glands, and infiltrates or proliferates into the center of peripheral reactive lymphoid follicles...
April 2, 2024: European Journal of Gastroenterology & Hepatology
https://read.qxmd.com/read/38625039/prevalence-of-geriatric-impairments-and-frailty-categorization-among-real-world-patients-with-multiple-myeloma-a-prospective-cohort-study-mfrail
#17
JOURNAL ARTICLE
Imran Haider, Darryl P Leong, Martha Louzada, Arleigh McCurdy, Gregory R Pond, Ruthanne Cameron, Mohammed Aljama, Alissa Visram, Tanya M Wildes, Hira Mian
There is limited knowledge regarding the prevalence of geriatric impairments and frailty among patients with multiple myeloma (MM) in a real-world setting. This study evaluated the distribution of frailty profiles among 116 patients with newly diagnosed or relapsed MM, using four common frailty scales. The proportion of patients classified as frail varied significantly, ranging from 15.5% to 56.9%, due to differences in how frailty was operationalized between each frailty measure. Functional, cognitive, and mobility impairments were common overall and irrespective of performance status...
April 16, 2024: Leukemia & Lymphoma
https://read.qxmd.com/read/38623748/response-to-lorlatinib-rechallenge-in-a-case-of-alk-rearranged-metastatic-nsclc-with-a-resistance-mutation-to-second-generation-tkis
#18
JOURNAL ARTICLE
Rita Leporati, Daniela Miliziano, Teresa Beninato, Laura Mazzeo, Sara Manglaviti, Marta Brambilla, Mario Occhipinti, Arsela Prelaj, Claudia Proto, Giuseppe Lo Russo
INTRODUCTION: Several anaplastic lymphoma kinase (ALK) tyrosine kinase inhibitors (TKIs) have been developed for the treatment of echinoderm microtubule-associated protein-like 4 (EML4)-ALK-rearranged non-small cell lung cancer (NSCLC), with the newer generation agents brigatinib, alectinib and lorlatinib showing prolonged responses. With the increasing number of target therapies available, the optimal sequence is yet to be defined, as resistance profiles may evolve over time and in response to sequential ALK inhibitors...
April 16, 2024: Tumori
https://read.qxmd.com/read/38623661/clinical-features-of-non-hodgkin-lymphoma-associated-hemophagocytic-syndrome-a-retrospective-study
#19
JOURNAL ARTICLE
Chunxiu Wu, Huiyong Liu, Jianlan Chen
BACKGROUND: This study aims to improve the understanding of lymphoma-associated hemophagocytic syndrome, and find effective methods to identify and manage this fatal disease. METHODS: Patients diagnosed with non-Hodgkin lymphoma-associated hemophagocytic syndrome from January 2008 to December 2022 in our center were included. Univariate and multivariate analyses were also conducted using the Cox proportional hazards model. RESULTS: Among 26 patients, 22 patients were diagnosed with T/NK cell lymphoma, while 4 patients were diagnosed with diffuse large B cell lymphoma...
April 1, 2024: Clinical Laboratory
https://read.qxmd.com/read/38623120/cranial-nerve-iii-palsy-as-the-first-sign-of-carcinomatous-meningitis-from-non-hodgkin-s-lymphoma
#20
Gabriel Velez Oquendo, Sergio Alcantar, Sonu Gupta
Carcinomatous meningitis (CM) is characterized by the multifocal dissemination of malignant cells into the cerebrospinal fluid (CSF), pia mater, and subarachnoid space. Involvement can occur in the advanced stage of malignancy, causing multifocal involvement and a wide array of symptoms. Diagnosis requires suspicions and a multimodal approach that includes imaging, lumbar puncture, and diagnostic laboratory evaluation. This case represents a female with a history of non-Hodgkin's lymphoma (NHL) and venous thromboembolism on chronic anticoagulation who presented due to acute encephalopathy, hallucinations, and right cranial nerve III palsy for 10 days before arrival...
March 2024: Curēus
keyword
keyword
4098
1
2
Fetch more papers »
Fetching more papers... Fetching...
Remove bar
Read by QxMD icon Read
×

Save your favorite articles in one place with a free QxMD account.

×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"

We want to hear from doctors like you!

Take a second to answer a survey question.